Side-by-Side Comparison
CJC-1295 vs Tesamorelin: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how CJC-1295 and Tesamorelin differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
CJC-1295
L3Also: CJC-1295 DAC, CJC-1295 without DAC, Modified GRF 1-29
A growth hormone-releasing hormone (GHRH) analog studied for its ability to increase growth hormone and IGF-1 levels.
Also: Egrifta, TH9507
An FDA-approved GHRH analog used for HIV-associated lipodystrophy, with research into broader metabolic and cognitive applications.
Side-by-side comparison
| Attribute | CJC-1295 | Tesamorelin |
|---|---|---|
| Primary mechanism | GHRH Receptor Agonism | GHRH Receptor Agonism |
| FDA status | Banned from Compounding (Category 2) | FDA Approved |
| Evidence level | Emerging Clinical Evidence | FDA Approved |
| Human trials | Yes (3+ indexed) | Yes (12+ indexed) |
| Studies indexed | 24 total (5 human, 12 animal) | 36 total (18 human, 8 animal) |
| Primary uses researched | Growth hormone release, Body composition, Recovery | Visceral fat reduction, HIV lipodystrophy, Cognitive function (research) |
| Administration routes | subcutaneous | subcutaneous |
| Molecular weight | 3367.97 Da | 5135.93 Da |
| Amino acids | 30 | 44 |
| Category | growth hormone | growth hormone |
| WADA status | Prohibited | Prohibited |
Key differences
Mechanism. Both compounds share the same primary mechanism (ghrh receptor agonism), so differences between them are driven by pharmacokinetics, selectivity, and clinical data rather than mechanism class.
Regulatory status. CJC-1295 is classified as banned from compounding (category 2); Tesamorelin is classified as fda approved. Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. Tesamorelin sits at a higher evidence level (L5) than CJC-1295 (L3) under PeptideMark's L1–L5 methodology.
Research focus. Published research on CJC-1295 has concentrated on growth hormone release, body composition, recovery. Research on Tesamorelin has concentrated on visceral fat reduction, hiv lipodystrophy, cognitive function (research). These research programs have limited overlap, and comparisons are most useful when readers are evaluating adjacent therapeutic goals.
Safety snapshot
| Attribute | CJC-1295 | Tesamorelin |
|---|---|---|
| Documented effects | 8 total | 9 total |
| Serious events | 0 | 0 |
| Common events | 2 | 5 |
| Black box warning | No | No |
| Contraindications | 4 listed | 4 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Injection site reactions | Injection site reactions |
Strengths & limitations
CJC-1295
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Prohibited in competitive sport under WADA
Tesamorelin
Strengths
- FDA-approved with established regulatory record
- Strong evidence base (L5)
- Multiple human clinical trials (12+ indexed)
Limitations
- Prohibited in competitive sport under WADA
Representative studies
CJC-1295
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, et al. · Journal of Clinical Endocrinology & Metabolism (2006)
CJC-1295 DAC produced dose-dependent, sustained increases in GH and IGF-1 with cumulative effects from repeated dosing — the foundational human pharmacokinetic data.
PubMed 16352683Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, Bhatt DL. · Journal of Clinical Endocrinology & Metabolism (2006)
CJC-1295 preserves pulsatile GH secretion during continuous stimulation — the enhanced trough GH levels (not pulse amplitude) drive the IGF-1 increase.
PubMed 17018654Tesamorelin
Tesamorelin, a Growth Hormone–Releasing Factor Analogue, Reduces Visceral Fat in HIV-Infected Patients
Falutz J, et al. · Annals of Internal Medicine (2007)
Tesamorelin reduced visceral adipose tissue by 15.4% compared to placebo, without worsening glucose tolerance.
PubMed 17909207REDUCE-1: Tesamorelin in HIV-Associated Lipodystrophy — A Randomized Controlled Trial
Grunfeld C, Thompson M, Brown SJ, et al. · AIDS (2006)
Tesamorelin reduced visceral AT by 18.3% versus 8.3% placebo (p<0.001); improvement sustained at 26 weeks post-treatment.
PubMed 16816556Frequently asked
What is the main difference between CJC-1295 and Tesamorelin?
CJC-1295 is a growth hormone-releasing hormone (ghrh) analog studied for its ability to increase growth hormone and igf-1 levels. Its primary mechanism is ghrh receptor agonism. Tesamorelin is an fda-approved ghrh analog used for hiv-associated lipodystrophy, with research into broader metabolic and cognitive applications. Its primary mechanism is ghrh receptor agonism. The two differ in regulatory status (Banned from Compounding (Category 2) vs FDA Approved), strength of evidence (L3 vs L5), and the primary conditions for which each is researched.
Is CJC-1295 or Tesamorelin FDA approved?
CJC-1295: Placed on FDA Category 2 list. Not approved for human use. Previously available from compounding pharmacies as a growth hormone secretagogue. Tesamorelin: FDA-approved in 2010 as Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
How does the evidence base compare?
CJC-1295 has 24 indexed studies (5 human, 12 animal) and is rated Emerging Clinical Evidence. Tesamorelin has 36 indexed studies (18 human, 8 animal) and is rated FDA Approved. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can CJC-1295 and Tesamorelin be compared directly?
Yes — both compounds share the growth hormone category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are CJC-1295 and Tesamorelin commonly stacked together?
There is no widely documented stacking protocol combining CJC-1295 and Tesamorelin in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, CJC-1295 or Tesamorelin?
CJC-1295 has 8 documented side effects (0 serious). Tesamorelin has 9 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are CJC-1295 and Tesamorelin administered?
Both are administered via subcutaneous. Practical dosing differences come down to frequency, concentration, and titration schedule rather than route of administration.
Which is better, CJC-1295 or Tesamorelin?
"Better" depends on the therapeutic goal, regulatory context, and individual response. CJC-1295 is most researched for growth hormone release and body composition; Tesamorelin is most researched for visceral fat reduction and hiv lipodystrophy. FDA status also matters: Banned from Compounding (Category 2) for CJC-1295 vs FDA Approved for Tesamorelin. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
CJC-1295 →
Full profile
Tesamorelin →